# MoonLake Immunotherapeutics: financial statements, quarterly

MLTX · Nasdaq · CIK 1821586 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/mltx.md) · [Financials](/companies/mltx/financials.md) · [Filings](/companies/mltx/filings.md) · [Insiders](/companies/mltx/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/mltx/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development | $m | [7.6](/filings/0001821586-24-000029.md) | [8.1 d](/filings/0001821586-26-000002.md) | [13.0](/filings/0001821586-25-000011.md) | [23.7](/filings/0001821586-25-000018.md) | [35.7](/filings/0001821586-25-000022.md) | [40.4 d](/filings/0001821586-26-000002.md) | [36.5](/filings/0001821586-26-000007.md) | [49.8](/filings/0001821586-26-000010.md) | [60.6](/filings/0001821586-25-000022.md) | [56.0 d](/filings/0001821586-26-000002.md) | [54.5](/filings/0001821586-26-000007.md) | [50.2](/filings/0001821586-26-000010.md) |
| Operating income | $m | [(13.0)](/filings/0001821586-24-000029.md) | [(15.0) d](/filings/0001821586-26-000002.md) | [(19.8)](/filings/0001821586-25-000011.md) | [(30.6)](/filings/0001821586-25-000018.md) | [(43.1)](/filings/0001821586-25-000022.md) | [(49.6) d](/filings/0001821586-26-000002.md) | [(47.5)](/filings/0001821586-26-000007.md) | [(60.7)](/filings/0001821586-26-000010.md) | [(71.4)](/filings/0001821586-25-000022.md) | [(65.2) d](/filings/0001821586-26-000002.md) | [(70.0)](/filings/0001821586-26-000007.md) | [(61.7)](/filings/0001821586-26-000010.md) |
| Interest expense | $m | not reported | not reported | [0.0](/filings/0001821586-25-000011.md) | [0.0](/filings/0001821586-25-000018.md) | [0.0](/filings/0001821586-25-000022.md) | [0.0 d](/filings/0001821586-26-000002.md) | [0.0](/filings/0001821586-26-000007.md) | [2.0](/filings/0001821586-26-000010.md) | [3.2](/filings/0001821586-25-000022.md) | [2.0 d](/filings/0001821586-26-000002.md) | [2.3](/filings/0001821586-26-000007.md) | [2.6](/filings/0001821586-26-000010.md) |
| Income tax | $m | [0.0](/filings/0001821586-24-000029.md) | [0.0 d](/filings/0001821586-26-000002.md) | [0.1](/filings/0001821586-25-000011.md) | [0.1](/filings/0001821586-25-000018.md) | [0.1](/filings/0001821586-25-000022.md) | [0.0 d](/filings/0001821586-26-000002.md) | [0.2](/filings/0001821586-26-000007.md) | [0.1](/filings/0001821586-26-000010.md) | [0.1](/filings/0001821586-25-000022.md) | [0.2 d](/filings/0001821586-26-000002.md) | [0.6](/filings/0001821586-26-000007.md) | [0.1](/filings/0001821586-26-000010.md) |
| Net income | $m | [(9.4)](/filings/0001821586-24-000029.md) | [(7.4) d](/filings/0001821586-26-000002.md) | [(13.7)](/filings/0001821586-25-000011.md) | [(24.3)](/filings/0001821586-25-000018.md) | [(35.4)](/filings/0001821586-25-000022.md) | [(45.6) d](/filings/0001821586-26-000002.md) | [(39.9)](/filings/0001821586-26-000007.md) | [(55.2)](/filings/0001821586-26-000010.md) | [(69.7)](/filings/0001821586-25-000022.md) | [(62.4) d](/filings/0001821586-26-000002.md) | [(69.7)](/filings/0001821586-26-000007.md) | [(61.8)](/filings/0001821586-26-000010.md) |
| Diluted EPS | $ per share | [(0.18)](/filings/0001821586-24-000029.md) | not reported | [(0.22)](/filings/0001821586-25-000011.md) | [(0.39)](/filings/0001821586-25-000018.md) | [(0.56)](/filings/0001821586-25-000022.md) | not reported | [(0.63)](/filings/0001821586-26-000007.md) | [(0.87)](/filings/0001821586-26-000010.md) | [(1.10)](/filings/0001821586-25-000022.md) | not reported | [(0.98)](/filings/0001821586-26-000007.md) | [(0.84)](/filings/0001821586-26-000010.md) |
| Basic EPS | $ per share | [(0.18)](/filings/0001821586-24-000029.md) | not reported | [(0.22)](/filings/0001821586-25-000011.md) | [(0.39)](/filings/0001821586-25-000018.md) | [(0.56)](/filings/0001821586-25-000022.md) | not reported | [(0.63)](/filings/0001821586-26-000007.md) | [(0.87)](/filings/0001821586-26-000010.md) | [(1.10)](/filings/0001821586-25-000022.md) | not reported | [(0.98)](/filings/0001821586-26-000007.md) | [(0.84)](/filings/0001821586-26-000010.md) |

- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [318](/filings/0001821586-23-000022.md) | [451](/filings/0001821586-25-000006.md) | [458](/filings/0001821586-24-000020.md) | [343](/filings/0001821586-24-000025.md) | [376](/filings/0001821586-24-000029.md) | [180](/filings/0001821586-26-000002.md) | [272](/filings/0001821586-25-000011.md) | [307](/filings/0001821586-25-000018.md) | [351](/filings/0001821586-25-000022.md) | [335](/filings/0001821586-26-000010.md) | [298](/filings/0001821586-26-000007.md) | [478](/filings/0001821586-26-000010.md) |
| Current assets | $m | [500](/filings/0001821586-23-000022.md) | [514](/filings/0001821586-25-000006.md) | [554](/filings/0001821586-24-000020.md) | [537](/filings/0001821586-24-000025.md) | [512](/filings/0001821586-24-000029.md) | [474](/filings/0001821586-26-000002.md) | [506](/filings/0001821586-25-000011.md) | [455](/filings/0001821586-25-000018.md) | [411](/filings/0001821586-25-000022.md) | [422](/filings/0001821586-26-000010.md) | [397](/filings/0001821586-26-000007.md) | [570](/filings/0001821586-26-000010.md) |
| Total assets | $m | [500](/filings/0001821586-23-000022.md) | [527](/filings/0001821586-25-000006.md) | [564](/filings/0001821586-24-000020.md) | [545](/filings/0001821586-24-000025.md) | [518](/filings/0001821586-24-000029.md) | [478](/filings/0001821586-26-000002.md) | [511](/filings/0001821586-25-000011.md) | [460](/filings/0001821586-25-000018.md) | [414](/filings/0001821586-25-000022.md) | [424](/filings/0001821586-26-000010.md) | [400](/filings/0001821586-26-000007.md) | [574](/filings/0001821586-26-000010.md) |
| Current liabilities | $m | [10.3](/filings/0001821586-23-000022.md) | [10.0](/filings/0001821586-25-000006.md) | [8.9](/filings/0001821586-24-000020.md) | [12.3](/filings/0001821586-24-000025.md) | [20.1](/filings/0001821586-24-000029.md) | [22.5](/filings/0001821586-26-000002.md) | [24.0](/filings/0001821586-25-000011.md) | [27.4](/filings/0001821586-25-000018.md) | [48.4](/filings/0001821586-25-000022.md) | [45.5](/filings/0001821586-26-000010.md) | [46.1](/filings/0001821586-26-000007.md) | [45.4](/filings/0001821586-26-000010.md) |
| Total liabilities | $m | [10.6](/filings/0001821586-23-000022.md) | [13.0](/filings/0001821586-25-000006.md) | [11.7](/filings/0001821586-24-000020.md) | [14.8](/filings/0001821586-24-000025.md) | [22.7](/filings/0001821586-24-000029.md) | [24.5](/filings/0001821586-26-000002.md) | [98.7](/filings/0001821586-25-000011.md) | [102](/filings/0001821586-25-000018.md) | [123](/filings/0001821586-25-000022.md) | [120](/filings/0001821586-26-000010.md) | [146](/filings/0001821586-26-000007.md) | [146](/filings/0001821586-26-000010.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001821586-26-000002.md) | [73.0](/filings/0001821586-25-000011.md) | [73.4](/filings/0001821586-25-000018.md) | [73.7](/filings/0001821586-25-000022.md) | [74.1](/filings/0001821586-26-000010.md) | [99.0](/filings/0001821586-26-000007.md) | [99.5](/filings/0001821586-26-000010.md) |
| Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [425](/filings/0001821586-23-000022.md) | [496](/filings/0001821586-25-000006.md) | [543](/filings/0001821586-24-000020.md) | [521](/filings/0001821586-24-000025.md) | [488](/filings/0001821586-24-000029.md) | [447](/filings/0001821586-26-000002.md) | [408](/filings/0001821586-25-000011.md) | [354](/filings/0001821586-25-000018.md) | [289](/filings/0001821586-25-000022.md) | [304](/filings/0001821586-26-000010.md) | [254](/filings/0001821586-26-000007.md) | [428](/filings/0001821586-26-000010.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Short-term borrowings: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(9.3) d](/filings/0001821586-24-000029.md) | [(12.3) d](/filings/0001821586-26-000002.md) | [(14.9)](/filings/0001821586-25-000011.md) | [(27.9) d](/filings/0001821586-25-000018.md) | [(25.3) d](/filings/0001821586-25-000022.md) | [(48.5) d](/filings/0001821586-26-000002.md) | [(38.1)](/filings/0001821586-26-000007.md) | [(54.5) d](/filings/0001821586-26-000010.md) | [(44.5) d](/filings/0001821586-25-000022.md) | [(58.8) d](/filings/0001821586-26-000002.md) | [(66.3)](/filings/0001821586-26-000007.md) | [(55.6) d](/filings/0001821586-26-000010.md) |
| Capital expenditure | $m | [0.0 d](/filings/0001821586-24-000029.md) | [0.3 d](/filings/0001821586-26-000002.md) | [0.2](/filings/0001821586-25-000011.md) | [0.0 d](/filings/0001821586-25-000018.md) | [0.1 d](/filings/0001821586-25-000022.md) | [0.2 d](/filings/0001821586-26-000002.md) | [0.0](/filings/0001821586-26-000007.md) | [0.0 d](/filings/0001821586-26-000010.md) | [0.0 d](/filings/0001821586-25-000022.md) | [0.0 d](/filings/0001821586-26-000002.md) | [0.0](/filings/0001821586-26-000007.md) | [0.0 d](/filings/0001821586-26-000010.md) |
| Share repurchases | $m | [0.0 d](/filings/0001821586-24-000029.md) | [0.0 d](/filings/0001821586-25-000006.md) | [0.0](/filings/0001821586-24-000020.md) | [0.0 d](/filings/0001821586-24-000025.md) | [0.0 d](/filings/0001821586-24-000029.md) | [0.0 d](/filings/0001821586-25-000006.md) | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [36.9](/filings/0001821586-23-000022.md) | [39.1](/filings/0001821586-24-000020.md) | [43.7](/filings/0001821586-24-000025.md) | [53.5](/filings/0001821586-24-000029.md) | [62.6](/filings/0001821586-25-000011.md) | [62.9](/filings/0001821586-25-000018.md) | [62.9](/filings/0001821586-25-000022.md) | [63.2](/filings/0001821586-26-000007.md) | [63.3](/filings/0001821586-26-000010.md) | [63.4](/filings/0001821586-25-000022.md) | [71.3](/filings/0001821586-26-000007.md) | [73.9](/filings/0001821586-26-000010.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 85,106,685 at 2026-08-01, from the cover of the [10-Q filed 2026-08-10](/filings/0001821586-26-000010.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.